

Effect of laser photocoagulation and bevacizumab intravitreal in proliferative diabetic retinopathy: review on biomarkers of oxidative stress

by Habibah Muhiddin

Submission date: 15-Jun-2021 08:51PM (UTC+0700)

Submission ID: 1606929720

File name: bevacizumab_intravitreal_in_prolifertive_diabeti_retinopathy.pdf (532.96K)

Word count: 5255

Character count: 26801

Clinical Research

4

Effect of laser photocoagulation and bevacizumab intravitreal in proliferative diabetic retinopathy: review on biomarkers of oxidative stress

Andi A. Victor,¹ Tjahjono D. Gondhowiardjo,¹ Sarwono Waspadji,² Septelia I. Wanandi,³ Adang Bachtiar,⁴ Franciscus D. Suyatna,⁵ Habibah Muhiddin,⁶

¹ Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

² Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

³ Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

⁴ Department of Administration and Health Policy, Faculty of Public Health, Universitas Indonesia, Jakarta, Indonesia

⁵ Department of Pharmacology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

⁶ Department of Ophthalmology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia

20

Abstrak

Latar belakang: Penelitian ini bertujuan membandingkan pengaruh fotokoagulasi laser dan bevacizumab intravitreal (BIV) terhadap penanda biologis stres oksidatif, antara lain aktivitas aldehid dehidrogenase (ALDH) plasma, kadar malondialdehid (MDA), aktivitas superoxide dismutase (SOD) dan kadar vitreal vascular endothelial growth factor (VEGF) pada penyandang retinopati diabetik (RD) proliferatif.

Metode: Penelitian ini merupakan uji klinis, prospektif, acak, tersamar tunggal di Rumah Sakit Cipto Mangunkusumo antara Februari 2011 - Juni 2013. Sebanyak 72 mata dari 69 penyandang RD proliferatif dirandomisasi menjadi 4 kelompok: 1) kontrol yang langsung menjalani vitrektomi sesuai indikasi (n = 18); 2) fotokoagulasi laser pra-vitrektomi (n = 18); 3) BIV pra-vitrektomi (n = 18); dan 4) kombinasi BIV dan fotokoagulasi laser pra-vitrektomi (n = 18). One-way ANOVA digunakan untuk perbandingan parameter stres oksidatif.

Hasil: Rerata aktivitas ALDH plasma pada kelompok 1, 2, 3 dan 4 masing-masing $0,034 \pm 0,02$; $0,027 \pm 0,02$; $0,025 \pm 0,02$ dan $0,031 \pm 0,11$ IU/mg protein ($p = 0,66$), kadar MDA vitreal $1,661 \pm 1,21$; $1,557 \pm 1,32$; $1,717 \pm 1,54$ dan $1,501 \pm 1,09$ nmol/mL ($p = 0,96$), dan aktivitas SOD $0,403 \pm 0,50$; $0,210 \pm 0,18$; $0,399 \pm 0,49$ dan $0,273 \pm 0,32$ U/mL ($p = 0,38$). Sedangkan rerata kadar VEGF vitreal adalah $0,356 \pm 0,60$; $0,393 \pm 0,45$; $0,150 \pm 0,24$ dan $0,069 \pm 0,13$ pg/mL menunjukkan perbedaan bermakna ($p = 0,05$). VEGF pada kelompok 4 lima kali lebih rendah dibandingkan kelompok kontrol ($p = 0,05$).

Kesimpulan: Kombinasi BIV dan fotokoagulasi laser berpengaruh terhadap MDA dan VEGF vitreal, namun tidak terhadap aktivitas ALDH plasma dan SOD vitreal. Kombinasi BIV dengan fotokoagulasi laser perlu dilakukan pada RD proliferatif.

Keywords: bevacizumab, diabetic retinopathy, laser photocoagulation, oxidative stress

2

pISSN: 0853-1773 • eISSN: 2252-8083 • <http://dx.doi.org/10.13181/mji.v23i2.756> • Med J Indones. 2014;23:79-86

Correspondence author: Andi A. Victor, arvimadao@yahoo.com

Copyright © 2014 Authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original author and source are properly cited.

Abstract

Background: This study was aimed to compare the effect of laser photocoagulation (LF), intravitreal bevacizumab (IVB) and combined treatments on biomarkers of oxidative stress such as aldehyde dehydrogenase (ALDH), malondialdehyde (MDA) level, superoxide dismutase (SOD) activities, and vitreal vascular endothelial growth factor (VEGF) on proliferative diabetic retinopathy (DR) patients.

Methods: In this single blind randomized clinical trial, 72 eyes from 69 cases of proliferative DR in Cipto Mangunkusumo Hospital between February 2011 - June 2013 were randomized into 4 groups : 1) control (n = 18); 2) LF pre-vitrektomy (n = 18); 3) IVB pre-vitrektomy (n = 18); and 4) combined IVB and LF pre-vitrektomy (n = 18). One-way ANOVA was used to compare oxidative stress parameters in the four groups.

Results: There were no statistically significant differences in the average plasma ALDH activity (0.034 ± 0.02 ; 0.027 ± 0.02 ; 0.025 ± 0.02 ; 0.031 ± 0.11 IU/mg protein; $p = 0.66$), vitreal MDA level (1.661 ± 1.21 ; 1.557 ± 1.32 ; 1.717 ± 1.54 ; 1.501 ± 1.09 nmol/mL; $p = 0.96$) and SOD activity (0.403 ± 0.50 ; 0.210 ± 0.18 ; 0.399 ± 0.49 ; 0.273 ± 0.32 U/mL; $p = 0.38$) among these four groups, respectively. However, the VEGF vitreal level (pg/mL) showed a statistically significant difference (0.356 ± 0.60 ; 0.393 ± 0.45 ; 0.150 ± 0.24 ; 0.069 ± 0.13 ; $p = 0.05$). The VEGF level in combined group was five times lower than the control group ($p = 0.05$).

Conclusion: Combined treatments of DR by IVB and LF were correlated with lower vitreal MDA and plasma VEGF level, but did not have any effect on plasma ALDH and vitreal SOD in proliferative DR. Combined treatments with IVB and LF are recommended for the management of proliferative DR patients.

1

<http://mji.ui.ac.id>

Diabetic retinopathy (DR) is a retinal vascular complication in patients with diabetes mellitus (DM) due to long term uncontrolled blood glucose levels.^{1,2} Diabetic retinopathy is the most common retinal vascular disorder found in Cipto Mangunkusumo Hospital. Between 2004-2009, among 3988 DR patients in RSCM, 61.7% were having non proliferative DR while the other 38.3% were having proliferative DR. In 2010-2012 the percentage of proliferative DR patients increased to 47.9%.³

In DR, retinal ischemia occurs due to microvascular occlusion and capillary nonperfusion.² In this ischemic state, retina underwent oxidative stress and formed a compound that will stimulate free radical reactions and pathological lipid peroxidation,⁴ forming an aldehyde compound that is highly reactive and cytotoxic such as malondialdehyde (MDA).⁵⁻⁷ Superoxide dismutase (SOD) is an antioxidant enzyme that acts to protect cells from the effects of oxidative stress. However, the low concentrations of SOD were found in people with DM.⁸

Free radicals and aldehyde compounds will increase the activity of the aldehyde dehydrogenase (ALDH) enzyme.⁹ Gondhowiardjo¹⁰ reported ALDH activity in the cornea, lens, aqueous humor and retina. Hasibuan¹¹ further reported the differences in diabetic patient plasma ALDH activity. ALDH activity in plasma of diabetic patients without diabetic retinopathy was higher than patients with diabetic retinopathy. ALDH activity in plasma is influenced by many abnormalities in other organs. Nevertheless, it will be very beneficial to know more about how ALDH activity in plasma level and its association with vitreal MDA as a substrate of ALDH activity in the vitreous, vitreal SOD and vitreal vascular endothelial growth factor (VEGF) in patients with intravitreal bevacizumab (IVB), an anti-VEGF agent, administration and/or laser photocoagulation (LF) as the treatments for proliferative diabetic retinopathy.

METHODS

The protocol of this study has been approved by the Ethic Research Committee, Faculty of Medicine Universitas Indonesia with letter number 352/PT02.FK/ETIK/2011 dated 16 June 2011.

The study was designed as a prospective, single-blind randomized clinical trial. Between February 2011 and June 2013, type 2 DM patients with

<http://mji.ui.ac.id>

proliferative diabetic retinopathy were considered for enrollment into the study. Patients enrolled in this study underwent systemic evaluation which include anamnesis (duration of DM and DM medication), measurement of blood pressure, and serum levels of HbA1C, blood glucose level as well as ocular inspection including best corrected visual acuity (BCVA) using the Snellen Chart (converted to logMAR), intraocular pressure, fundus photography and central macular thickness (CMT) as measured by Ocular Computed Tomography (OCT). An improvement in visual acuity was defined as two or more improved lines of BCVA.

Inclusion and exclusion criteria

Inclusion criteria for this study were patients with proliferative diabetic retinopathy who are willing to participate by signing informed consent, and agree to follow the steps of the study. Exclusion criteria were patients with systemic disease such as uncontrolled hypertension (systolic > 180 mmHg or diastolic > 110 mmHg), hemostatic disorder or using anticoagulant therapy, impaired renal function (hemodialysis patients), history of stroke and congestive heart failure, patients who ever had previous vitrectomy or got IVB or intravitreal triamcinolone or LF. Drop out criteria was patient who did not come for follow-up at 2-4 weeks after LF or IVB treatment and refused to undergo vitrectomy.

Patient enrollment

Seventy two eyes of 69 proliferative diabetic retinopathy patients obtained from Vitreoretina Division, Department of Ophthalmology, Faculty of Medicine-RSCM were randomized into 4 groups. Control group (1) (n = 18) underwent direct vitrectomy according to clinical indication, LF group (2) (n = 18) underwent a pre-vitrectomy laser photocoagulation, IVB group (3) (n = 18) received intravitreal bevacizumab (IVB) pre-vitrectomy and the group 4 received combination of LF and IVB pre-vitrectomy (n = 18). Informed consent form was signed by all study participants after explanation of the nature and possible consequences of the study.

Biomarkers of oxidative stress measurement

Plasma ALDH activity⁹ and MDA level¹²⁻¹⁴ were measured using spectrophotometry method. The MnSOD enzyme specific activity was biochemically

determined using RanSOD® kit.¹⁵ VEGF level measurement was determined using ELISA system kit.¹⁶

5 Follow-up protocol

Follow-up visits were scheduled at 2nd, 4th and 12th weeks after surgery. Follow-up evaluation includes BCVA and OCT examination. At each visit, patients were also asked about the perceived side effects.

5 Outcome measures

The primary outcomes measured were the value of plasma ALDH, VEGF, MDA and SOD in the vitreous body of the four groups. Secondary outcomes measured include the proportion of the increase in visual acuity and reduction of the proportion of CMT measured by OCT 2 weeks, 4 weeks, and 12 weeks after intervention.

5 Statistical analysis

Results were analyzed using computerized statistic program. Visual acuity was converted to logMAR before statistical analysis. Statistical test comparing two mean ALDH activity, MDA level, SOD activity, VEGF level, central macular thickness and visual acuity in each group were performed by one-way ANOVA. Multivariate analysis performed by two-way ANOVA/multi regression analysis.

RESULTS

In this study, male and female subjects ratio was 51.4% : 48.6%. The age range of the subjects was 26 - 67 year old with the average age was 50.33 ± 8.236 year old. A total of 70.8% of these study subjects had been diagnosed with type 2 DM for less than 10 years, while the rest was diagnosed as type 2 DM for more than 10 years.

There was no statistically significant difference in the baseline clinical features in these four groups, with the exception of the average glycemic control status. There was statistically significant difference between group 3 and 4 and group 1 and 2 of the average glycemic control status of the subjects. The other variables showed no statistically significant differences (Table 1).

Primary outcomes: biomarkers values

In each group, respectively, the average plasma ALDH activity (IU/mg protein) were 0.034 ± 0.02; 0.027 ± 0.02; 0.025 ± 0.02; 0.031 ± 0.1, p = 0.66, vitreal MDA level (nmol/mL) were 1.661 ± 1.21; 1.557 ± 1.32; 1.717 ± 1.54; 1.501 ± 1.09, p = 0.96, vitreal SOD activity (U/mL) were 0.403 ± 0.50; 0.210 ± 0.18; 0.399 ± 0.49; 0.273 ± 0.32, p = 0.38, and vitreal VEGF level (pg/mL) were 0.356 ± 0.14; 0.393 ± 0.45; 0.150 ± 0.24; 0.069 ± 0.13, p = 0.05 (Table2).

Table 1. Baseline characteristics of diabetic retinopathy patients in the four groups

	Group			
	Control	LF	IVB	IVB + LF
Age (years) ± SD	51.00 ± 6.95	51.00 ± 6.62	50.44 ± 9.87	48.89 ± 9.53
Male/Female	12/6	7/11	10/8	6/12
DM duration (years) ± SD	9.83 ± 6.25	9.11 ± 4.77	8.44 ± 6.88	9.67 ± 5.122
HbA1c (%) ± SD	8.13 ± 1.54	8.45 ± 2.26	6.87 ± 1.16	7.23 ± 1.45
Anti-hyperglycemic drug usage				
Insulin	3	6	1	2
SU and insulin	2	2	1	3
Non-SU and insulin	2	2	1	3
SU	9	7	11	7
Non-SU	2	1	4	3
CMT (µm) ± SD	360.20 ± 191.35	452.10 ± 327.57	464.22 ± 297.77	519.00 ± 319.19
Pre-vitreotomy CMT (µm) ± SD	428.44 ± 226.77	452.83 ± 362.17	409.17 ± 231.60	480.39 ± 264.20
Visual acuity (logMAR) ± SD	1.58 ± 0.55	1.79 ± 0.26	1.83 ± 0.49	1.84 ± 0.32
Pre-vitreotomy visual acuity (logMAR) ± SD	1.61 ± 0.52	1.79 ± 0.24	1.80 ± 0.37	1.87 ± 0.28

SU: Sulphonylurea, CMT: Central macular thickness, DM: Diabetes mellitus, IVB: Intravitreal bevacizumab, LF: Laser photocoagulation

The activity of plasma ALDH in the IVB group showed no statistically significant differences among all groups ($p = 0.66$). The highest plasma ALDH activity was found in the patients with bad glycemic control status, while the lowest was found in the good glycemic control status patients (Table 3).

In the LF group, the vitreal MDA level was lower than the control group. The vitreal MDA level in the combination group was the lowest among all group. However, the differences of vitreal MDA level in all groups were not statistically significant ($p = 0.96$).

The activity of vitreal SOD showed no statistically significant differences ($p = 0.38$). The highest SOD activity was found in the patients with good glycemic control status, while the lowest was found in the bad glycemic control status (Table 3).

The lowest VEGF level was found in the combination group (0.069 pg/mL). The VEGF level in combination group was five times lower than the control group and statistically significant. In the IVB group the VEGF level was also low (0.150 pg/mL), twice lower than the control group. The VEGF level of LF group and the control group were comparable. The differences of vitreal VEGF level in all groups were statistically significant ($p = 0.05$).

Visual acuity

Visual acuity in the LF group was improved compared to the other groups. However the improvement occurred only until the 4th week. The visual acuity in this group decreased when measured in the 12th week. However in the 12th week the visual acuity in this group was still better than the other groups (Figure 1).




Figure 1. The changes of visual acuity among the four groups in 2nd, 4th, and 12th week

Table 2. Comparison of biomarkers values among the four groups

	Group				p*
	Control	LF	IVB	IVB + LF	
Plasma ALDH activity (U/mg protein) ± SD	0.034 ± 0.02	0.027 ± 0.02	0.025 ± 0.02	0.031 ± 0.11	0.66
Vitreal MDA level (nmol/mL) ± SD	1.661 ± 1.21	1.557 ± 1.32	1.717 ± 1.54	1.501 ± 1.09	0.96
Vitreal SOD activity (U/mL) ± SD	0.403 ± 0.50	0.210 ± 0.18	0.399 ± 0.49	0.273 ± 0.32	0.38
Vitreal VEGF level (pg/mL) ± SD	0.356 ± 0.60	0.393 ± 0.45	0.150 ± 0.24	0.069 ± 0.13	0.05

*ANOVA analysis, ALDH: Aldehyde dehydrogenase, MDA: Malondialdehyde, SOD: Superoxide dismutase, VEGF: Vascular endothelial growth factor, LF: Laser photocoagulation, IVB: Intravitreal bevacizumab

Table 3. Associations between biomarkers and glycemic control status (HbA1c) (n = 72)

	Group				p*
	Control	LF	IVB	IVB + LF	
Plasma ALDH activity (U/mg protein) ± SD	0.034 ± 0.02	0.027 ± 0.02	0.025 ± 0.02	0.031 ± 0.11	0.66
Vitreal MDA level (nmol/mL) ± SD	1.661 ± 1.21	1.557 ± 1.32	1.717 ± 1.54	1.501 ± 1.09	0.96
Vitreal SOD activity (U/mL) ± SD	0.403 ± 0.50	0.210 ± 0.18	0.399 ± 0.49	0.273 ± 0.32	0.38
Vitreal VEGF level (pg/mL) ± SD	0.356 ± 0.60	0.393 ± 0.45	0.150 ± 0.24	0.069 ± 0.13	0.05

*Using Kruskal-Wallis analysis, ALDH: Aldehyde dehydrogenase, MDA: Malondialdehyde, SOD: Superoxide dismutase, VEGF: Vascular endothelial growth factor, LF: Laser photocoagulation, IVB: Intravitreal bevacizumab

This study also showed that ALDH activity less than 0.024 IU was associated with improved visual acuity with a sensitivity of 0.54 and specificity of 0.45.

Central macular thickness

Central macular thickness was reduced in control, LF and combination groups until week-4, and it increased again when measured in week-12. The exception was in the IVB group, in which the CMT is continuously reduced until week-12. However, the biggest reduction in CMT was found in the combination group (Figure 2).

It was also shown that the changes in CMT were not associated with the level of vitreal MDA, the activity of vitreal SOD and the level of vitreal VEGF with the p value respectively 0.09, 0.64, and 0.13.

The plasma ALDH activity below 0.024 IU in this study was associated with reduced CMT with sensitivity of 0.54 and specificity of 0.53. From the OCT, this study also found a method to grade the fibrovascular membrane. This finding is shown in figure 3.

Complications

In this study, 11 cases (15.3%) of recurrent vitreal

hemorrhage and hyphema post vitrectomy were found. Other complication was retinal detachment which was found in 5 cases (6.9%). Fifteen of 72 (20.8%) subjects developed increase in lens opacities. Other complication comprised glaucoma in 5 cases (6.9%) and optic nerve atrophy in 1 case (1.4%). The number of complications occurred in each group is shown on table 4.




Figure 2. The changes of CMT among the four groups in 2nd, 4th, and 12th Week




Figure 3. Grading of fibrovascular membrane: A) Grade 0 no fibrovascular membrane in every quadrant; B) Grade 1 fibrovascular membrane in 1 quadrant; C) Grade 2 fibrovascular membrane in 2 quadrants; D) Grade 3 fibrovascular membrane in 2 quadrants; E) Grade 4 fibrovascular membrane in all quadrants

Table 4. Complications of the treatments with laser photocoagulation, intravitreal bevacizumab, or combination (n = 72)

Complications	n (%)				Total
	Control	LF	IVB	IVB + LF	
Recurrent vitreous hemorrhage and / or hyphema	2 (2.8)	1 (1.4)	3 (4.2)	5 (6.9)	11 (15.4)
Retinal detachment	1 (1.4)	1 (1.4)	0	3 (4.2)	5 (6.9)
Lens opacity	5 (6.9)	4 (5.6)	2 (2.8)	4 (5.6)	15 (20.8)
Glaucoma	1 (1.4)	3 (4.2)	1 (1.4)	0	5 (6.9)
Optic nerve atrophy	0	1 (1.4)	0	0	1 (1.4)

LF: Laser photocoagulation, IVB: Intravitreal bevacizumab

DISCUSSION

Intravitreal bevacizumab and LF is the current treatment used in the proliferative DR patients as the adjuncts for the vitrectomy. Various studies were done especially on IVB to measure the clinical outcomes of the therapies on these proliferative DR patients. The vitrectomy on those studies appeared safe and effective on reducing the recurrent vitreal hemorrhage, ²⁹beit without the benefit of visual acuity.¹⁷ Our study was aim to measure the effect of these therapies on the biomarkers of oxidative stress. Oxidative stress is the underlying mechanism of DR, thus by measuring it; the effectivity of the therapies can be accurately measured.

Laser photocoagulation in DR is aimed at ischemic retinal tissue to turn them into scar tissue thus decreasing the oxidative stressed caused by the high oxygen demand. However before these effect can be achieved, LF causes a physical trauma due to its thermal effect which in tum worsen the oxidative stress and increase the aldehyde level.¹⁸

The administration of IVB as anti-VEGF influenced the biochemical processes that happened in DR patients. Intravitreal bevacizumab will decrease the VEGF level and consequently restore the retinal vascular permeability.^{19,20} These processes will inhibit the oxidative stress and aldehyde formation.⁴ However IVB cannot reduce the ischemic retinal area. Thus its effect is limited by its duration of action.²¹

The ALDH activity in all groups showed no statistically significant and clinically important results. These finding was due to biochemical processes that happened because of LF, IVB, and combination of both of them were only a small proportion of the whole biochemical processes in the body. However, ¹⁶ndhowiardjo¹⁰ found that plasma ALDH activity in type 2 DM patients without DR

is higher than plasma ALDH activity in type 2 DM patients with DR. Plasma ALDH activity decrease as the ¹⁷tion of type 2 DM increase and is associated with blood glucose level and the use of anti-diabetic drugs.¹⁰

⁶The MDA level in the combination group was lower than the other groups while in the IVB group the value was higher than the other groups. Intravitreal bevacizumab is given to inhibit the formation of VEGF which can cause microvascular occlusion, telangiectasia and retinal ischemia.² Through inhibition of VEGF formation, the retinal ischemia can be minimized and so do the oxidative stress. Subsequently, the end products of aldehyde such as MDA will not be formed. However, the IVB effect is limited by the duration of its action²¹ and also the ischemic retina cannot be treated as in the LF. Therefore the vitreal MDA level will increase because of the retinal ischemia that is not resolved.

⁶The activity of vitreal SOD in the combination group was not lower than the control or IVB groups. However, high SOD activity will overcome the oxidative stress²² and in tum will lower the formation of VEGF.⁴ Nevertheless, this is consistent with the finding in this study that the high activity of SOD will be followed by lower VEGF level.

Laser photocoagulation is known to increase the oxidative status of the ²⁶na. In this study, the activity of SOD in the LF group was lower than the control group, even though the difference was not statistically significant. The low SOD activity can be caused by the bad glycemic control status in the LF group.

In this study, the lowest vitreal VEGF level was found in the combination group and is consistent with Jing, et al²³ study. The IVB group also showed low VEGF level. The effect of LF in decreasing VEGF levels was twice lower than the IVB.

30

Visual acuity in the LF group was improved better compared to the other groups even though it only occurred until the 4th week. The visual acuity in this group decreased when measured in the 12th week. However in the 12th week the visual acuity in this group was still better than the other groups (Figure 1). Nevertheless, visual acuity should not be used as a sole indicator of the success of the therapies because it is affected by many factors. It was showed that in the combination group the visual acuity was the worst before any intervention was made, thus the visual acuity after the treatment could not be expected to improve very much.

In this study, CMT was reduced in all group, with the biggest reduction occurred in the combination group (Figure 2). This finding showed that both of these therapies have a synergistic effect in reducing the CMT in proliferative DR patients and is consistent with Stefansson, et al²⁴ study.

This study showed that plasma ALDH activity below 0.024 IU was associated with improved CMT with sensitivity of 0.54 and specificity of 0.53. Similarly, the ALDH activity less than 0.024 IU was associated with improved visual acuity with a sensitivity of 0.54 and specificity of 0.45. Thus proliferative DR patients with plasma ALDH activity below 0.024 IU post vitrectomy will show a better improvement in visual acuity and CMT. However the sensitivity and specificity of this test as a prognostic factor is not high.

The correlation between MDA and VEGF showed negative correlation in which the high MDA level is associated with low VEGF level. This negative correlation is not found in the control group. However the correlations in all of these groups were weak and were not statistically significant. These showed that the negative correlation was caused by the intervention.

The correlation between VEGF and SOD in this study showed a positive correlation, in which high VEGF levels was associated with high SOD activity, with the exception in the IVB group. These correlations, however, were weak and were not statistically significant.

Theoretically, oxidative stress will promote the formation of superoxide radical ($O_2^{\cdot-}$)⁴ which in turn will cause the lipid peroxidation of cell membrane²⁵ and cause the formation of MDA and then VEGF.^{4,26} Superoxide dismutase acts to eliminate $O_2^{\cdot-}$ so

MDA will not be formed.²² Consequently the stress oxidative and retinal ischemia is reduced and the formation of VEGF is inhibited.

It was also shown that the changes in CMT were not associated with the level of vitreal MDA, VEGF and the activity of vitreal SOD. The changes in CMT could be influenced by the activity of another enzyme or biomarkers such as $Na^+-K^+-ATPase$ or prostaglandin-E2.²⁷ The reduction of $Na^+-K^+-ATPase$ will disrupt the function of retinal epithelial barrier that can lead to macula oedema. The levels of vitreal MDA and VEGF and vitreal SOD activity are dynamic and constantly changing while the change in CMT is the result of a long processes.

In conclusion, combination of LF and IVB did not influence the activities of plasma ALDH and vitreal SOD. However, these combination was significantly associated with lower vitreal VEGF level. These combination was also associated with lower vitreal MDA level even though the association was not statistically significant. These finding showed that the combination of both therapies decreased the oxidative stress that occurs on proliferative DR. Thus, combination of both IVB and LF should be used in the management of proliferative DR patient. Moreover, the measurement of plasma ALDH can also be used as a prognostic factor for determining the visual acuity and CMT although the sensitivity and specificity is not high. However, more study with more sensitive measurement of plasma ALDH should be conducted to get a more accurate ALDH measurement.

10

Conflict of interest

The authors hereby affirm that there is no conflict of interest in this study.

REFERENCES

1. Chew EY, Ferris III FL. Nonproliferative diabetic retinopathy. In: Ryan SJ, editor. Retina. 5th ed. St. Louis: Mosby; 2006. p.1271-84.
2. Frank RN. Etiologic mechanism in diabetic retinopathy. In: Ryan SJ, editor. Retina. 5th ed. St. Louis: Mosby; 2006. p.1241-70.
3. Vitreoretinal Division. Department of Ophthalmology Faculty of Medicine Universitas Indonesia. (2013). [Prevalence of diabetic retinopathy]. Unpublished raw data.
4. Kowluru RA, Chan P-S. Oxidative stress and diabetic retinopathy. *Exp Diabet Res.* 2007;2007:1-12.
5. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. *Br J Ophthalmol.* 2008;92(4):548-51.

6. Atamer Y, Koçyiğit Y, Atamer A, Mete N, Canoruç N, 33rak G. Alterations of erythrocyte and plasma lipid peroxides as well as antioxidant mechanism in patients with type II diabetes mellitus (NIDDM). *Tr J Medical Sciences*. 1998;28:143-8.
7. Mancino R, Di Pierro D, Varesi C, Cerulli A, Feraco A, Cedrone C, et al. Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy. *Mol Vis*. 2011;17:1298-304.
8. Samuel TV, Murthy DSI, Dattatreya K, Babu PS, Johncy SS. Impaired antioxidant defence mechanism in diabetic retinopathy. *JCDR*. 2010;4(6):3429-36.
9. Gondhowiardjo TD. Characterization of Human Corneal Aldehyde Dehydrogenase [dissertation]. Netherlands: The Netherlands Ophthalmic Research Institute; 1992.
10. Gondhowiardjo TD. The role of enzymatic exploration in ocular diabetics. In: Kadarisman RS, editor. *Understanding ocular diabetics*. Jakarta: Department of Ophthalmology Faculty of Medicine Universitas Indonesia; 1999. p. 32-40.
11. Hasibuan H. *Aktivitas Enzim ALDH pada Retinopati Diabetik* [thesis]. Mount Pleasant (MI): Universitas Indonesia; 1997. Indonesian.
12. Suyatna FD, Priyanto, Istiantoro J, Sadikin M. Oxidant and antioxidant status of police officer in the city and rural area. *Med J Indones*. 2004;13(2):77-80.
13. Oen LH, Utomo H, Suyatna FD, Hanafiah A, Asikin N. Plasma lipid peroxides in coronary heart disease. *Int J Clin Pharmacol Ther Toxicol* 1992;30(3):77-80.
14. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. *Biochem J*. 1966;99(3):667-76.
15. Randox Laboratories [Internet]. Ransod superoxide dismutase manual. Available from: <http://www.randox.com>.
16. Ishizaki E, Takai S, Ueki M, Maeno T, Maruichi M, 21iyama T, et al. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. *Am J Ophthalmol*. 2006;141(1):129-34.
17. Sinawat S, Rattanapakorn T, Sanguansak T, Yospaiboon Y, Sinawat S. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. *Eye (Lond)*. 2013;27(12):1391-6.
18. Galetović D, Bojić L, Bučan K, Karlica D, Lesin M, Znaor L. The role of oxidative stress after retinal laser photocoagulation in nonproliferative diabetic retinopathy. *Coll Antropol*. 2011;35(3):835-40.
19. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, et al. Efficacy of 1.25 mg versus 2.5 mg intravitreal bevacizumab for diabetic macular edema. six month results of a randomized controlled trial. *Retina*. 2009;29(3):292-9.
20. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bavacizumab in high risk proliferative diabetic retinopathy. *Retina*. 2009;29(4):516-22.
21. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. *Am J Ophthalmol*. 2008;146(4):508-12.
22. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. *Diabetes*. 2004;53(suppl1):S110-8.
23. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma 7ncentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. *Retina*. 2011;31(1):161-8.
24. Stefánsson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. *Invest Ophthalmol Vis Sci*. 1990;31(2):284-9.
25. Durmuş M, Yılmaz HR, Uz E, N Özçelik. The effect of 38eic acid phenethyl ester (CAPE) treatment on levels of MDA, NO, and antioxidant enzymes activities in retinas of streptozotocin-induced diabetic rats. *Turk J Med Sci*. 2008;38(6):525-30.
26. Halliwell B, Gutteridge JM. Lipid peroxidation, oxygen radicals, cell damage and antioxidant therapy. *Lancet*. 1984;1(8391):1396-7.
27. Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. *Br J Ophthalmol*. 2004;88(1):145-51.

Effect of laser photocoagulation and bevacizumab intravitreal in proliferative diabetic retinopathy: review on biomarkers of oxidative stress

ORIGINALITY REPORT

16%

SIMILARITY INDEX

11%

INTERNET SOURCES

14%

PUBLICATIONS

6%

STUDENT PAPERS

PRIMARY SOURCES

- 1** Submitted to Sriwijaya University 2%
Student Paper
- 2** Jeanne A. Pawitan. "Autoclaved bone graft usage revisited", Medical Journal of Indonesia, 2014 2%
Publication
- 3** innovareacademics.in 1%
Internet Source
- 4** www.library.gunadarma.ac.id 1%
Internet Source
- 5** Quan Zhang, Ting Zhang, Hong Zhuang, Zhongcui Sun, Yaowu Qin. "Single-Dose Intravitreal Conbercept before Panretinal Photocoagulation as an Effective Adjunctive Treatment in Chinese Proliferative Diabetic Retinopathy", Ophthalmologica, 2019 1%
Publication
- 6** iscs.org.ir 1%
Internet Source

7	journals.plos.org Internet Source	<1 %
8	www.karger.com Internet Source	<1 %
9	pubmed.ncbi.nlm.nih.gov Internet Source	<1 %
10	Syaiful A. Hadi, Jefri Sukmawan. "Effect of lyophilized amniotic membrane, hyaluronic acid, and their combination in preventing adhesion after tendon repair in New Zealand white rabbits", Medical Journal of Indonesia, 2014 Publication	<1 %
11	Submitted to Universitas Indonesia Student Paper	<1 %
12	www.tandfonline.com Internet Source	<1 %
13	www.healio.com Internet Source	<1 %
14	www.mdpi.com Internet Source	<1 %
15	www.pkuph.cn Internet Source	<1 %
16	Shinsuke Nakamura, Tomomi Masuda, Shuuji Sakurai, Hideaki Kawakami et al. "Adiponectin	<1 %

is a pathological factor for intraocular angiogenesis", Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018

Publication

17

"APASL Abstracts, Bali 2005", Liver International, 12/2005

Publication

<1 %

18

"Abstracts", Respirology, 11/2011

Publication

<1 %

19

Stephen M. Conti. "The use of intravitreal corticosteroids, evidence-based and otherwise", Current Opinion in Ophthalmology, 06/2006

Publication

<1 %

20

Susi Endrini, Asmah Rahmat, Patimah Ismail, Y.H. Taufiq-Yap. "Cytotoxic effect of γ -sitosterol from Kejibeling (*Strobilanthes crispus*) and its mechanism of action towards *c-myc* gene expression and apoptotic pathway", Medical Journal of Indonesia, 2015

Publication

<1 %

21

pdfs.semanticscholar.org

Internet Source

<1 %

22

synapse.koreamed.org

Internet Source

<1 %

23

Septelia Inawati Wanandi, Elisna Syahrudin, Reni Paramita, Ay Ly Margareth. "Expression and Genotype of Manganese Superoxide Dismutase (MnSOD) in Lung Cancer Cells of Smoker Patients", Makara Journal of Health Research, 2010

Publication

<1 %

24

W. B. Cho. "Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy", British Journal of Ophthalmology, 07/01/2010

Publication

<1 %

25

Wendy M. Saragih, Siska Sulistiowati, Nur Haryono, Bambang B. Siswanto, Nani Hersunarti, Amiliana M. Soesanto. "Case report of secondary hypertension due to renal artery stenosis in young patient", Medical Journal of Indonesia, 2014

Publication

<1 %

26

actamedindones.org

Internet Source

<1 %

27

medsci.org

Internet Source

<1 %

28

www.molvis.org

Internet Source

<1 %

29	"Poster presentations abstracts", Osteoporosis International, 2007 Publication	<1 %
30	H Shahid. "The management of retinal vein occlusion: is interventional ophthalmology the way forward?", British Journal of Ophthalmology, 2006 Publication	<1 %
31	biomedpharmajournal.org Internet Source	<1 %
32	cdt.amegroups.com Internet Source	<1 %
33	www.ajol.info Internet Source	<1 %
34	www.frontiersin.org Internet Source	<1 %
35	www.scribd.com Internet Source	<1 %
36	Clinical Strategies in the Management of Diabetic Retinopathy, 2014. Publication	<1 %
37	mehdijournal.com Internet Source	<1 %
38	app.trdizin.gov.tr Internet Source	<1 %

39

Andi Arus Victor, Ratna Sitompul. "Chapter 5 Proliferative Diabetic Retinopathy: An Overview of Vitreous Immune and Biomarkers", IntechOpen, 2018

Publication

<1 %

Exclude quotes On

Exclude matches < 5 words

Exclude bibliography On